Skip to search formSkip to main contentSkip to account menu

Mutant p53 Activator COTI-2

Known as: COTI2, Coti-2 
An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models.
6040Background: The p53 tumor suppressor is mutated in more than half of all cancers. COTI-2, an oral 3rd-generation… 
2018
2018
Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?
e13121Background: The identification of a targeted therapy for patients with triple-negative breast cancer (TNBC) is one of the… 
2018
2018
PO-037 Targeting mutant p53 with COTI-2: a new approach for the treatment of patients with triple-negative breast cancer?
Introduction The identification of a targeted therapy for triple-negative breast cancer (TNBC) is one of the most urgent needs in… 
2016
2016
COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway
2016
2016
The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism
IntroductionTP53 mutations are rare ( METHODS AND RESULTS A total of 10 AML cell lines were exposed to COTI-2 for 72 hours and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)